Opthea completes A$171.5m institutional capital raise, opens A$55.9m retail offer for retinal disease therapy development.
Opthea, a clinical-stage biopharmaceutical company, has completed the institutional component of its capital raising, raising approximately A$171.5 million (US$113.2m). The fully underwritten retail entitlement offer will open on 19 June and close on 10 July, aiming to raise an additional A$55.9m. The funds will support the development of novel therapies for retinal diseases, including wet AMD.
June 14, 2024
3 Articles